Enveda Raises $150M Series D Funding to Reach Unicorn Status, Enrolls First Patient in Lead Program, and Adds Mikael Dolsten to Board of Directors

Enveda获得1.5亿美元D轮融资，成为独角兽企业，首个主导项目患者入组，并任命Mikael Dolsten为董事会成员。

Pipeline expansion: Company advances first-in-class clinical pipeline to address large unmet medical needs in Atopic Dermatitis, Asthma, Inflammatory Bowel Disease, and Obesity

管线扩展：公司推进一流临床管线，以解决特应性皮炎、哮喘、炎症性肠病和肥胖症中大量未满足的医疗需求。

Platform scale: Company doubles down on its platform, delivering 12+ development candidates from life’s chemistry 4× faster and 10× cheaper than industry average

平台规模：公司加倍投入其平台，从生命的化学中交付12个以上的开发候选项目，速度比行业平均水平快4倍，成本低10倍。

BOULDER, Colo., September 4, 2025-- Enveda, a clinical-stage biotech company pioneering the discovery and development of a new generation of small-molecule drugs derived from life’s chemistry, today announced three major milestones: the close of its $150 million oversubscribed Series D financing, enrolling of the first patient in a Phase 1b clinical trial for lead program ENV-294 in atopic dermatitis, and the appointment of former Pfizer Chief Scientific Officer and President of Worldwide R&D, Dr.

科罗拉多州博尔德，2025年9月4日——Enveda是一家处于临床阶段的生物技术公司，致力于从生命化学中发现并开发新一代小分子药物。该公司今日宣布了三项重要里程碑：超额认购的1.5亿美元D轮融资结束，领先项目ENV-294针对特应性皮炎的1b期临床试验首例患者入组，以及前辉瑞首席科学官兼全球研发总裁Dr.

Mikael Dolsten, to its Board of Directors..

米卡埃尔·多尔斯特（Mikael Dolsten）入选董事会。

The round was led by Premji Invest with participation from new and existing investors Baillie Gifford, Kinnevik, Lingotto Investment Management, Peakline Partners, FPV, Socium Ventures, Dimension, Level Ventures, Henry Kravis, IA Ventures, and Lux Capital. This follows a $150 million Series C closing in February that included Sanofi, bringing the company's total funding to $517 million..

本轮融资由Premji Invest领投，新投资者和现有投资者Baillie Gifford、Kinnevik、Lingotto Investment Management、Peakline Partners、FPV、Socium Ventures、Dimension、Level Ventures、Henry Kravis、IA Ventures和Lux Capital参与。此前，该公司于2月完成了1.5亿美元的C轮融资，投资方包括赛诺菲，使得公司总融资额达到5.17亿美元。

In just five years from seed financing, Enveda has scaled from platform proof-of-concept into one of the fastest-growing techbio companies, advancing a wholly-owned, internally generated pipeline of novel small molecules that now spans discovery through the clinic. Enveda’s rapid trajectory has been enabled by its proprietary chemical sequencer, the first platform to systematically decode previously inaccessible chemistry in living systems using machine learning and metabolomics..

从种子轮融资开始仅五年时间，Enveda就从平台概念验证发展成为增长最快的科技生物公司之一，推进了一条完全自有、内部生成的新型小分子管线，现已覆盖从发现到临床的全过程。Enveda的快速发展得益于其专有的化学测序仪，这是首个利用机器学习和代谢组学系统解码生命系统中先前无法获取的化学信息的平台。

“Enveda is proving that it’s possible to generate novel and first-in-class small molecule therapeutics at an unprecedented speed, scale, and efficiency,” said Akshay Rai, Principal, Healthtech and Biotech at Premji Invest. “We believe there is a large unexplored search space for novel medicines, and Enveda has built the platform to translate life’s chemistry into treatments that could be transformative for millions of patients across the globe.

“Enveda正在证明，以前所未有的速度、规模和效率生成新颖且首创的小分子治疗药物是可能的，”Premji Invest健康科技和生物技术主管Akshay Rai表示。“我们认为，新型药物的研究领域存在巨大的未开发空间，而Enveda已经建立了将生命化学转化为可能对全球数百万患者产生变革性影响的治疗平台。”

This team is turning breakthrough science into medicines at a pace that is exceptionally rare, and are on their way to building what could be an industry-defining company.”.

这个团队以前所罕见的速度将突破性的科学成果转化为药物，并正在打造一家可能成为行业标杆的公司。

The Series D funding will advance multiple clinical programs into Phase 1b and Phase 2 trials across diseases affecting more than 100 million adults in the U.S. alone. The funds will also support new IND filings in the coming months, positioning the company to deliver key clinical milestones across atopic dermatitis, asthma, inflammatory bowel disease, obesity, and more..

D轮融资将推动多个临床项目进入1b期和2期试验，针对仅美国就超过一亿成年人所受影响的疾病。这笔资金还将支持未来几个月的新药临床试验申请（IND）提交，使公司能够在特应性皮炎、哮喘、炎症性肠病、肥胖症等领域实现关键的临床里程碑。

Key Clinical Milestone Highlights the Power of a Unique Approach

关键临床里程碑凸显独特方法的力量

Nearly half of all oral medicines originate from molecules found in nature, yet it is estimated that 99% of nature’s chemical diversity remains unexplored due to the complexity and cost of isolating, identifying, and characterizing individual compounds. Enveda has built one of the world’s largest collections of natural samples and made its chemistry searchable, using AI that can analyze thousands of molecules at once and a fully automated high-throughput lab to map therapeutic properties.

几乎所有的口服药物中，近一半源自自然界中的分子，但据估计，由于分离、识别和表征单个化合物的复杂性和成本，大自然99%的化学多样性仍未被探索。Enveda建立了世界上最大的天然样本库之一，并利用人工智能使其化学成分可被搜索，这种人工智能可以同时分析数千种分子，并通过全自动高通量实验室来绘制治疗特性。

By putting billions of years of evolutionary intelligence into the hands of drug hunters for the first time, Enveda is accelerating the discovery of first-in-class medicines more than fourfold and pioneering a faster, more precise path to transformative therapies..

通过首次将数十亿年的进化智能交到药物猎人手中，Enveda将首创新药的发现速度提高了四倍以上，并开创了一条更快、更精确的变革性治疗路径。

“At Enveda, we are learning from life’s chemical code,” said Viswa Colluru, Founder and CEO, Enveda. “Nature has been running the most sophisticated R&D program on Earth for billions of years, yet nearly all of its chemistry remains unexplored. By making this hidden language searchable and pairing it with AI, automation, and metabolomics, we are transforming how medicines are discovered.

“在Enveda，我们正在从生命的化学密码中学习，”Enveda创始人兼首席执行官Viswa Colluru表示。“大自然已经在地球上运行了最复杂的研发计划数十亿年，但其几乎所有的化学物质仍未被探索。通过使这种隐藏的语言可被搜索，并将其与人工智能、自动化和代谢组学相结合，我们正在改变药物发现的方式。”

We’re building a generational company that changes the way the world understands and uses life’s chemistry, to deliver breakthroughs that can redefine medicine and transform industries.”.

我们正在打造一家世代相传的公司，它将改变世界对生命化学的理解和应用方式，带来可以重新定义医学并变革行业的突破性进展。

Today, Enveda has sixteen preclinical programs, more than a dozen development candidates, four IND-enabling programs, and one clinical program underway. This progress has been achieved in less time than it typically takes biotechs, which average more than seven years to bring their first new chemical entity into Phase 1 trials..

如今，Enveda公司拥有16个临床前项目、十多个开发候选药物、4个IND支持项目，并且有一个临床项目正在进行中。这一进展所用的时间比生物技术公司通常所需的时间要短，这些公司平均需要七年以上的时间才能将其首个新化学实体推进到一期临床试验。

ENV-294, Enveda’s lead program, is a first-in-class, oral anti-inflammatory small molecule derived from nature, discovered entirely on its platform. This candidate represents a completely new chemical class with a novel mechanism of action. It demonstrates kinase inhibitor-like and steroid-like best-in-disease preclinical efficacy in inflammatory disease models and a safety profile similar to biologics in toxicology studies.

ENV-294是Enveda的主导项目，是一种首创的、口服的抗炎小分子，源自天然，并完全在其平台上发现。该候选药物代表了一种全新的化学类别，具有独特的作用机制。在炎症疾病模型中，它展现出类似于激酶抑制剂和类固醇的最佳临床前疗效，同时在毒理学研究中显示出与生物制剂相似的安全性。

The Phase 1b trial in patients with moderate to severe atopic dermatitis follows successful Phase 1a results in healthy volunteers, where ENV-294 demonstrated favorable safety and tolerability in patients, with no dose-limiting toxicities or serious adverse events..

中度至重度特应性皮炎患者的1b期试验是在健康志愿者中取得成功的结果之后进行的，ENV-294在患者中表现出良好的安全性和耐受性，没有剂量限制性毒性和严重不良事件。

Esteemed Industry Veteran Dr. Mikael Dolsten Joins Board

尊敬的行业资深人士 Mikael Dolsten 博士加入董事会

Dr. Dolsten, credited with advancing more than 150 drug candidates into clinical studies and 36 approvals during his tenure at Pfizer as Chief Scientific Officer and President of Worldwide R&D, joins Enveda’s Board of Directors. Dr. Dolsten’s career has been defined by bold scientific bets that changed the trajectory of human health, with a track record of leading groundbreaking science from research to market.

在辉瑞担任首席科学官和全球研发总裁期间，多尔斯滕博士推动了150多种药物候选进入临床研究，并获得了36项批准，他将加入Enveda的董事会。多尔斯滕博士的职业生涯以大胆的科学决策为标志，这些决策改变了人类健康的轨迹，他有着将开创性科学从研究推向市场的成功记录。

“I’m proud to join Enveda, where the team has built the technology to harness the potential of life’s chemistry at scale,” said Dolsten..

“我很自豪能加入Enveda，这个团队已经开发出技术，能够大规模地利用生命化学的潜力，” Dolsten说。

About Enveda

关于Enveda

Enveda is a biotechnology company that learns from life’s chemistry to create better medicines faster. Enveda uses AI-powered tools to identify and characterize a wide range of molecules produced by living organisms, the vast majority of which have never been explored by science, creating a database of chemical biodiversity: the library of life.

Enveda是一家生物技术公司，通过研究生命化学来更快地创造更好的药物。Enveda利用人工智能工具识别和表征由生物体产生的各种分子，其中绝大多数从未被科学探索过，从而创建了一个化学生物多样性的数据库：生命的图书馆。

By growing, organizing, translating, and searching this unique library, Enveda learns from life’s evolved solutions to address today’s most pressing medical needs. For more information, visit https://enveda.com/..

通过增长、组织、翻译和搜索这个独特的库，Enveda从生命进化的解决方案中学习，以应对当今最紧迫的医疗需求。欲了解更多信息，请访问https://enveda.com/。

Contact:

联系人：

Media Contacts

媒体联系人

Enveda

恩维达

Natasha Alimchandani

纳塔莎·阿里姆昌达尼

natasha@enveda.com

natasha@enveda.com

(310) 428-6414

(310) 428-6414

KKH Advisors

KKH顾问公司

Kimberly Ha

金伯利·哈

kimberly.ha@kkhadvisors.com

金伯利·哈@kkhadvisors.com

(917) 291-5744

(917) 291-5744